Table 1

Main characteristics of the eligible studies
Study Patient's country Year TNM grading/UICC staging Technique Number of patients Antibody used, dilution Cutoff of CD133 positive Site
Coco Italy 2012 I–III IHC 137 Santa Cruz 100 > 5% Colon or Rectum
Hongo Japan 2012 I–IV IHC 303 Miltenyi Biotec 100 > 5% Colon or Rectum
Zhang China 2012 II–III IHC 125 Novus 150 ≥Score 4 colon
Xi China 2011 I–IV IHC 201 Abcam 200 ≥Score 5 Colon or Rectum
Lugli Switzerland 2010 I–IV Tissue microarray 1235 Cell Signaling 100 > 5% Colon or Rectum
Takahashi Japan 2010 I–IV IHC 151 Abcam 200 > 50% Colon or Rectum
Ong Australia 2010 I–IV Tissue microarray 501 Miltenyi Biotech 10 > 5% Colon or Rectum
Li China 2009 IIIB IHC 104 Abcam 150 ≥5% Colon or Rectum
Horst Germany 2009 I–II IHC 110 Cell Signaling 100 ≥50% Colon
Choi South Korea 2009 0–IV Tissue microarray 523 Santa Cruz 50 -- Colon or Rectum
Wang China 2009 0–IV IHC 73 Abcam 200 > 10% Rectal
Kojima Japan 2008 I–IV IHC 189 Miltenyi Biotech 100 > 10% Colon or Rectum

Wang et al.

Wang et al. BMC Cancer 2012 12:573   doi:10.1186/1471-2407-12-573

Open Data